Comparison of the pharmacokinetics of lamotrigine in patients with chronic renal failure and healthy volunteers

British Journal of Clinical Pharmacology

Volumn 43, Issue 1, 1997, Pages 23-27

  Wootton, R ^a   Soul Lawton, J ^a   Rolan, P E ^a,c   Fook Sheung, C T C ^a   Cooper, J D H ^b   Posner, J ^a  

^a WELLCOME RESEARCH LABORATORIES   (United Kingdom)

^b Clinical Innovations Ltd   (United Kingdom)

^c Skelton House   (United Kingdom)

Author keywords

Lamotrigine; Lamotrigine glucuronide; Pharmacokinetics; Renal failure

Indexed keywords

DRUG METABOLITE; LAMOTRIGINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; KIDNEY FAILURE; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; VOLUNTEER;

EID: 0031029933     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.1997.tb00028.x     Document Type: Article

References (19)

1. Miller AA, Wheatley P, Sawyer DA, Baxter MG, Roth B. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: I. anticonvulsant profile in mice and rats. Epilepsia 1986; 27: 483-489.
2. Leach MJ, Marden CM, Miller AA. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. neurochemical studies on the mechanism of action. Epilepsia 1986; 27: 490-497.
3. Binnie CD, Debets RMC, Englesman M, et al. Double-blind crossover trial of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy. Epilepsy Res 1989; 4: 222-229.
4. Rambeck B, Wolf P. Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet 1993; 25: 433-443.
5. Goa KL, Ross SR, Chrisp P. Lamotrigine: a review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1993; 46: 152-176.
6. Yuen AWC, Peck AW. Lamotrigine pharmacokinetics: oral and i.v. infusion in man. Br J Clin Pharmacol 1988; 26: 242P.
7. Cohen AF, Land GS, Breimer DD, Yuen AWC, Winton C, Peck AW. Lamotrigine, a new anticonvulsant: Pharmacokinetics in normal humans. Clin Pharmacol Ther 1987; 42: 535-541.
8. Cooper JDH, Turnell DC, Green B. Automated sequential trace enrichment of dialysates and robotics. A technique for the preparation of biological samples prior to high-performance liquid chromatography. J Chromatogr 1988; 456: 53-69.
9. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-34.
10. Reidenberg MM, Odar-Cederlof I, von Bahr C, Borga O, Sjoqvist F. Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function. N Engl J Med 1971; 285: 264-267.
11. Gugler R, Shoeman DW, Huffman DH, Cohlmia JB, Azarnoff DL. Pharmacokinetics of drugs in patients with the nephrotic syndrome. J Clin Invest 1975; 55: 1182-1189.
12. Gugler R, Mueller G. Plasma protein binding of valproic acid in healthy subjects and in patients with renal disease. Br J Clin Pharmacol 1978; 5: 441-446.
13. Miller AA, Sawyer DA, Roth B, et al. Lamotrigine. In New anticonvulsant drugs eds Meldrum S, Porter R, pp. 165-177, John Libbey, London, 1986.
14. Binnie CD, van Emde Boas W, Kasteleijn-Nolste-Trenite DGA, et al. Acute effects of lamotrigine (BW430C) in persons with epilepsy. Epilepsia 1986; 27: 248-254.
15. Jawad S, Yuen WC, Peck AW, et al. Lamotrigine: single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy. Epilepsy Res 1987; 1: 194-201.
16. Ramsay RE, Pellock JM, Garnett WR, et al. Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy. Epilepsy Res 1991; 10: 191-200.
17. Yuen AWC, Land G, Weatherley BC, Peck AW. Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol 1992; 33: 511-513.
18. Bernus I, Dickinson RG, Hooper WD, Eadie MJ. Inhibition of phenobarbitone N-glucosidation by valproate. Br J Clin Pharmacol 1994; 38: 411-416.
19. Posner J, Cohen AF, Land G, Winton C, Peck AW. The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert's syndrome). Br J Clin Pharmacol 1989; 28: 117-120.